about
Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinomaIntratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung AdenocarcinomaAberrant Signaling through the HER2-ERK1/2 Pathway is Predictive of Reduced Disease-Free and Overall Survival in Early Stage Non-Small Cell Lung Cancer (NSCLC) Patients.Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.Mitochondrial AKAP1 supports mTOR pathway and tumor growth.A new look at the ALK gene in cancer: copy number gain and amplification.Diagnosis of anaplastic lymphoma kinase rearrangement in cytological samples through a fluorescence in situ hybridization-based assay: Cytological smears versus cell blocks.Predictive biomarkers along gastric cancer pathogenetic pathways.Are tumor-infiltrating lymphocytes protagonists or background actors in patient selection for cancer immunotherapy?Detection of folate receptor-positive circulating tumor cells by ligand-targeted polymerase chain reaction in non-small cell lung cancer patients.CRISPR-barcoding in non small cell lung cancer: from intratumor genetic heterogeneity modeling to cancer therapy application.Correction: Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma.Immunohistochemistry for Cancer Stem Cells Detection: Principles and Methods.Crizotinib Response in a Late Relapse of ALK-positive Lung Adenocarcinoma.Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research studyCirculating tumor cells as emerging tumor biomarkers in lung cancer
P50
Q28553228-CFF77943-050A-4BEC-9348-BEB117B9FD35Q34586019-3B82C5C1-280B-4CBA-8C1A-54935E1AC392Q35793656-531A058C-0378-4E14-8632-F6654F373843Q37667783-A8958B8C-B803-420D-919F-A8D595947864Q38096472-8F831BDE-DA47-4011-8FB7-10746C42ABECQ38743093-7B28B82B-7D55-4E3A-A834-E000BFF7DD0DQ38751302-CEE4110C-EBA6-4B17-8838-86588DCBCF94Q38760747-E53EB524-1D41-4E68-B8B4-CBEA248FAA29Q38962364-6CC57A4D-A1D2-46D1-A8EE-8F46F23605E2Q39170872-A35359D5-4540-435B-AA5C-D46FE6923747Q39187442-78D862A6-10FC-43E9-930B-991AA33DC926Q42141860-15300BE0-443F-4463-8FD4-69716AFFCF8EQ42341991-5F90F095-9A81-429C-927E-14043D75DB32Q43202841-AE2F343E-8547-4F69-816B-41305E3633ADQ49544565-BB4017D9-691E-4843-A68B-55190EB801DDQ52844013-416B7F94-5565-47F5-A1DD-6B8F575937BCQ58774174-D6745EA4-426A-48D3-B046-E852D12714A3Q59012119-7FFD04E6-B8A8-4451-94F3-EC598EDFB42E
P50
name
Federica Zito Marino
@en
Federica Zito Marino
@nl
type
label
Federica Zito Marino
@en
Federica Zito Marino
@nl
prefLabel
Federica Zito Marino
@en
Federica Zito Marino
@nl